|
US645503A
(en)
|
1899-05-11 |
1900-03-13 |
Timothy Francis Crowley |
Cutter-gage for ice-cream, & c.
|
|
US953924A
(en)
|
1909-06-28 |
1910-04-05 |
Dow Wire & Iron Works |
Sliding door.
|
|
US20030040463A1
(en)
|
1996-04-05 |
2003-02-27 |
Wiegand Stanley J. |
TIE-2 ligands, methods of making and uses thereof
|
|
WO1998018914A1
(en)
|
1996-10-31 |
1998-05-07 |
Duke University |
Soluble tie2 receptor
|
|
US5919813C1
(en)
|
1998-03-13 |
2002-01-29 |
Univ Johns Hopkins Med |
Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
|
|
US5980929A
(en)
|
1998-03-13 |
1999-11-09 |
Johns Hopkins University, School Of Medicine |
Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
|
|
CA2368670C
(en)
|
1999-03-26 |
2012-06-05 |
Chitra Suri |
Modulation of vascular permeability by means of tie2 receptor activators
|
|
US6455035B1
(en)
|
1999-03-26 |
2002-09-24 |
Regeneron Pharmaceuticals, Inc. |
Angiopoietins and methods of use thereof
|
|
EP1046715A1
(en)
|
1999-04-23 |
2000-10-25 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
|
|
US6897201B2
(en)
*
|
2000-08-21 |
2005-05-24 |
Inspire Pharmaceuticals, Inc. |
Compositions and methods for the treatment of glaucoma or ocular hypertension
|
|
US7052695B2
(en)
|
2001-10-25 |
2006-05-30 |
Regeneron Pharmaceuticals, Inc. |
Angiopoietins and methods of treating hypertension
|
|
WO2003084565A2
(en)
|
2002-04-08 |
2003-10-16 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Ve-ptp as regulator of ve-cadherin mediated processes or disorders
|
|
AU2003231098A1
(en)
|
2002-04-25 |
2003-11-10 |
University Of Connecticut Health Center |
Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
|
|
US7507568B2
(en)
|
2002-09-25 |
2009-03-24 |
The Proctor & Gamble Company |
Three dimensional coordinates of HPTPbeta
|
|
US7226755B1
(en)
|
2002-09-25 |
2007-06-05 |
The Procter & Gamble Company |
HPTPbeta as a target in treatment of angiogenesis mediated disorders
|
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
US8298532B2
(en)
|
2004-01-16 |
2012-10-30 |
Regeneron Pharmaceuticals, Inc. |
Fusion polypeptides capable of activating receptors
|
|
HRP20110694T1
(hr)
|
2004-03-15 |
2011-12-31 |
Janssen Pharmaceutica Nv |
Novi spojevi kao modulatori opioidnog receptora
|
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
|
AU2005269716B2
(en)
|
2004-07-20 |
2011-01-27 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
|
US7691365B2
(en)
|
2004-09-28 |
2010-04-06 |
Aprogen, Inc. |
Methods of using chimeric coiled coil molecule to treat ischemic disease
|
|
HRP20110859T1
(hr)
|
2004-12-21 |
2011-12-31 |
Medimmune Limited |
Protutijela usmjerena na angiopoietin-2 i njihova upotreba
|
|
US7893040B2
(en)
|
2005-07-22 |
2011-02-22 |
Oculis Ehf |
Cyclodextrin nanotechnology for ophthalmic drug delivery
|
|
US20070154482A1
(en)
|
2005-09-12 |
2007-07-05 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
|
|
TW200744567A
(en)
*
|
2005-09-23 |
2007-12-16 |
Alcon Inc |
Phenylethylamine analogs and their use for treating glaucoma
|
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
|
JP5179373B2
(ja)
|
2005-12-15 |
2013-04-10 |
アストラゼネカ アクチボラグ |
癌を治療するためのアンジオポエチン−２アンタゴニストとＶＥＧＦ−Ａ、ＫＤＲ、及び／又はＦｌｔ１アンタゴニストの組合せ
|
|
HUE026496T2
(en)
|
2006-03-08 |
2016-06-28 |
Archemix Llc |
Complement-binding aptamers and anti-C5 agents for treating eye diseases
|
|
DE102006016426A1
(de)
*
|
2006-04-07 |
2007-10-11 |
Merck Patent Gmbh |
Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
|
|
EP3252079B8
(en)
|
2006-04-07 |
2020-09-09 |
Aerpio Therapeutics LLC |
Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
|
|
US7622593B2
(en)
|
2006-06-27 |
2009-11-24 |
The Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7589212B2
(en)
|
2006-06-27 |
2009-09-15 |
Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US8846685B2
(en)
|
2006-06-27 |
2014-09-30 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US20130023542A1
(en)
|
2006-06-27 |
2013-01-24 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7795444B2
(en)
|
2006-06-27 |
2010-09-14 |
Warner Chilcott Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
EP2076290B1
(en)
|
2006-10-27 |
2016-12-14 |
Sunnybrook Health Sciences Center |
Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
|
|
US8642067B2
(en)
|
2007-04-02 |
2014-02-04 |
Allergen, Inc. |
Methods and compositions for intraocular administration to treat ocular conditions
|
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
|
WO2009105774A2
(en)
|
2008-02-21 |
2009-08-27 |
Sequoia Pharmaceuticals, Inc. |
Amino acid inhibitors of cytochrome p450
|
|
CN109771421A
(zh)
|
2009-01-12 |
2019-05-21 |
爱尔皮奥治疗有限公司 |
治疗血管渗漏综合征的方法
|
|
US9096555B2
(en)
|
2009-01-12 |
2015-08-04 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome
|
|
AU2011312203C1
(en)
|
2009-01-12 |
2016-09-08 |
EyePoint Pharmaceuticals, Inc. |
Compositions and methods for treating ocular edema, neovascularization and related diseases
|
|
WO2010097800A1
(en)
*
|
2009-02-26 |
2010-09-02 |
Muhammad Abdulrazik |
Synergistic combination of bioactive compounds for lowering of intraocular pressure
|
|
ES2508290T3
(es)
|
2009-03-03 |
2014-10-16 |
Alcon Research, Ltd. |
Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo
|
|
AU2010221438C1
(en)
|
2009-03-03 |
2015-01-29 |
Alcon Research, Ltd. |
Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
|
|
US8883832B2
(en)
|
2009-07-06 |
2014-11-11 |
Aerpio Therapeutics Inc. |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
|
PL2451279T3
(pl)
|
2009-07-06 |
2019-09-30 |
Aerpio Therapeutics, Inc. |
Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych
|
|
RU2597844C2
(ru)
|
2010-07-12 |
2016-09-20 |
Тресхолд Фармасьютикалз, Инк. |
Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака
|
|
US20180092883A1
(en)
|
2010-10-07 |
2018-04-05 |
Aerpio Therapeutics, Inc. |
Phosphatase inhibitors for treating ocular diseases
|
|
WO2012073627A1
(ja)
|
2010-12-02 |
2012-06-07 |
丸善製薬株式会社 |
Ｔｉｅ２活性化剤、血管内皮増殖因子（ＶＥＧＦ）阻害剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤、並びに医薬品組成物
|
|
AU2012323856B2
(en)
|
2011-10-13 |
2017-05-25 |
EyePoint Pharmaceuticals, Inc. |
Methods for treating Vascular Leak Syndrome and cancer
|
|
HK1201196A1
(en)
|
2011-10-13 |
2015-08-28 |
Aerpio Therapeutics, Inc. |
Treatment of ocular disease
|
|
US20130190324A1
(en)
|
2011-12-23 |
2013-07-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Topical ocular drug delivery
|
|
CA2870341A1
(en)
|
2012-04-13 |
2013-10-17 |
The Johns Hopkins University |
Treatment of ischemic retinopathies
|
|
SG11201408538PA
(en)
|
2012-07-13 |
2015-02-27 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
JP6371765B2
(ja)
|
2012-07-31 |
2018-08-08 |
ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ |
糖尿病治療用医薬組成物
|
|
MX370543B
(es)
|
2012-10-11 |
2019-12-17 |
Ascendis Pharma Ophthalmology Div A/S |
Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
|
|
CA3240136A1
(en)
|
2012-11-08 |
2014-05-15 |
Clearside Biomedical, Inc. |
Methods and devices for the treatment of ocular diseases in human subjects
|
|
US20150290235A1
(en)
|
2012-11-23 |
2015-10-15 |
Ab Science |
Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
|
|
EP4101297A1
(en)
|
2013-03-15 |
2022-12-14 |
Aerpio Pharmaceuticals, Inc. |
Compositions, formulations and methods for treating ocular diseases
|
|
US20150050277A1
(en)
|
2013-03-15 |
2015-02-19 |
Aerpio Therapeutics Inc. |
Compositions and methods for treating ocular diseases
|
|
DK2983695T3
(da)
|
2013-04-11 |
2019-09-02 |
Sunnybrook Res Inst |
Fremgangsmåder, anvendelser og sammensætninger af tie2- agonister
|
|
WO2014203183A1
(en)
|
2013-06-20 |
2014-12-24 |
Novartis Ag |
Use of a vegf antagonist in treating macular edema
|
|
EP3010525A1
(en)
|
2013-06-20 |
2016-04-27 |
Novartis AG |
Use of a vegf antagonist in treating choroidal neovascularisation
|
|
US20160151410A1
(en)
|
2013-07-02 |
2016-06-02 |
The Trustees Of Columbia University In The City Of New York |
Clearance of bioactive lipids from membrane structures by cyclodextrins
|
|
US20160159893A1
(en)
|
2013-07-11 |
2016-06-09 |
Gabriela Burian |
Use of a VEGF Antagonist in Treating Retinopathy of Prematurity
|
|
CN105377891A
(zh)
|
2013-07-11 |
2016-03-02 |
诺华股份有限公司 |
Vegf拮抗剂在治疗儿童患者的脉络膜视网膜新生血管和通透性疾病中的应用
|
|
US9902767B2
(en)
|
2013-07-29 |
2018-02-27 |
Samsung Electronics Co., Ltd. |
Method of blocking vascular leakage using an anti-ANG2 antibody
|
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
|
JP6419794B2
(ja)
|
2013-10-01 |
2018-11-07 |
シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング |
主要な心臓有害事象に罹患する危険性を予測する方法
|
|
DK3062811T3
(da)
|
2013-11-01 |
2019-05-13 |
Regeneron Pharma |
Angiopoietin-baserede interventioner til behandling af cerebral malaria
|
|
US9994560B2
(en)
*
|
2014-03-14 |
2018-06-12 |
Aerpio Therapeutics, Inc. |
HPTP-β inhibitors
|
|
WO2015152416A1
(ja)
*
|
2014-04-04 |
2015-10-08 |
国立大学法人東北大学 |
眼圧降下剤
|
|
WO2015152415A1
(ja)
|
2014-04-04 |
2015-10-08 |
株式会社ダイゾー |
吐出容器
|
|
US9719135B2
(en)
|
2014-07-03 |
2017-08-01 |
Mannin Research Inc. |
Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
|
|
WO2016022813A1
(en)
|
2014-08-07 |
2016-02-11 |
Aerpio Therapeutics, Inc. |
Combination of immunotherapies with activators of tie-2
|
|
US20160082129A1
(en)
|
2014-09-24 |
2016-03-24 |
Aerpio Therapeutics, Inc. |
VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
|
|
TWI705827B
(zh)
|
2014-11-07 |
2020-10-01 |
瑞士商諾華公司 |
治療眼部疾病之方法
|
|
US20160144025A1
(en)
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
|
CN113713101B
(zh)
*
|
2015-09-23 |
2023-07-28 |
视点制药公司 |
用tie-2的激活剂治疗眼内压的方法
|
|
WO2020223209A1
(en)
*
|
2019-04-29 |
2020-11-05 |
Aerpio Pharmaceuticals, Inc. |
Tie-2 activators targeting the schlemm's canal
|